Table 1.
Test compounds and their inclusion criteria
| CAS | Compound | Abbreviation | Inclusion criteria | Reference | Supplier |
|---|---|---|---|---|---|
| 15687-27-1 | Ibuprofen | IBU | Negative control (OATP1C1) | Westholm et al. (2009) | Sigma-Aldrich |
| 20448-79-7 | 2-Amino-bicycloheptane-2-carboxylic acid | BCH | Negative control (OATP1C1) | Tohyama et al. (2004) | Sigma-Aldrich |
| 15307-79-6 | Diclofenac | DIC | OATP1C1 inhibitor | Westholm et al. (2009) | Fluka |
| 57-66-9 | Probenecid | PRB | OATP1C1/OAT4 inhibitor | Tohyama et al. (2004); Chen et al. (2023) | Sigma-Aldrich |
| 3599-32-4 | Indocyanine green | ICG | OATP1C1 inhibitor | Westholm et al. (2009) | Cayman Chemical |
| 60311-02-6 | Sulforhodamine 101 | SR101 | OATP1C1 inhibitor | Bakos et al. (2020) | Merck Life Science |
| 71-67-0 | Bromosulfophthalein | BSP | OATP1C1 substrate | Sugiyama et al. (2003) | Alfa Aesar |
| 878672-00-5 | Lesinurad | LESI | OAT4 inhibitor | Chen et al. (2023) | Merck Life Science |
| 51-52-5 | Propylthiouracil | PTU | TPO inhibitor | Friedman et al. (2016) | Sigma-Aldrich |
| 117-39-5 | Quercetin | QCT | TPO inhibitor | Friedman et al. (2016) | Merck Life Science |
| 1763-23-1 | Perfluorooctanesulfonic acid | PFOS | NIS inhibitor/TTR binding | Buckalew et al. (2020); Weiss et al. (2015) | Fluka |
| 73-22-3 | l-Tryptophan | TRP | LAT1/2 inhibitor | Chen et al. (2022a, b) | Sigma-Aldrich |
| 13292-46-1 | Rifampicin | RIF | OATP inhibitor | Chen et al. (2022a, b) | Sigma-Aldrich |
| 152-11-4 | Verapamil | VRP | OATP inhibitor | Chen et al. (2022a, b) | Sigma-Aldrich |
| 335-67-1 | Perfluorooctanoic acid | PFOA | TTR binding | Weiss et al. (2009) | Sigma-Aldrich |
| 87-86-5 | Pentachlorophenol | PCP | TTR binding | Hamers et al. (2006) | Sigma-Aldrich |
| 79-94-7 | Tetrabromobisphenol-A | TBBPA | TTR binding | Hamers et al. (2006) | Sigma-Aldrich |
| 115-09-3 | Methyl mercury | MeHg | MCT8 inhibitor | Wagenaars et al. (2023) | Sigma-Aldrich |
| 33889-69-9 | Silychristin | SY | MCT8-inhibitor | Johannes et al. (2016) | Merck Life Science |
| 80-05-7 | Bisphenol-A | BPA | MCT8-inhibitor | Wagenaars et al. (2023) | Sigma-Aldrich |
| 843-55-0 | Bisphenol-Z | BPZ | MCT8-inhibitor | Wagenaars et al. (2023) | TRC Canada |
| 1478-61-1 | Bisphenol-AF | BPAF | MCT8-inhibitor | Wagenaars et al. (2023) | Merck Life Science |
| 80-09-1 | Bisphenol-S | BPS | BPA-like | TRC Canada | |
| 620-92-8 | Bisphenol-F | BPF | BPA-like | Fluka | |
| 3380-34-5 | Triclosan | TCS | decreased brain T4 in pups | Gilbert et al. (2021) | Merck Life Science |
| 138261-41-3 | Imidacloprid | IMI | decreased plasma T4 in rats | Ibrahim et al. (2015) | Fluka |
| 4999-79-5 | β-Estradiol-3-sulfate | β-E3S | OAT4 substrate | Skwara et al. (2017) | Sigma-Aldrich |
| 69-93-2 | Uric acid | UA | OAT4 substrate | Skwara et al. (2017) | Sigma-Aldrich |
| 7400-08-0 | 4-Hydroxycinnamic acid | 4HCA | OAT4 substrate | Wong et al. (2011) | Merck Life Science |